Clinical Trials Logo

Jaundice; Malignant clinical trials

View clinical trials related to Jaundice; Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT06197984 Recruiting - Choledocholithiasis Clinical Trials

Antimicrobial Resistance in Acute Cholangitis

ARISE
Start date: January 8, 2024
Phase:
Study type: Observational [Patient Registry]

This study prospectively explores antimicrobial resistance in patients with acute cholangitis undergoing ERCP procedures. By analyzing patient profiles, microbial cultures, and treatment outcomes, the current study seeks to identify specific patterns of resistance, assess the effectiveness of current antimicrobial therapies, and explore potential strategies to optimize treatment regimens.

NCT ID: NCT06115564 Recruiting - Choledocholithiasis Clinical Trials

Microbiological Assessment of Bile in Patients Undergone to Endoscopic Retrograde Cholangiography (ERCP): the "Microbile Registry"

Microbile
Start date: July 1, 2022
Phase:
Study type: Observational

The study is a prospective evaluation of the microbial assessment in patients undergoing to ERC with naive papilla; the population includes all the indication to biliary drainage.

NCT ID: NCT05395013 Completed - Jaundice; Malignant Clinical Trials

Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)

NEOSTENT
Start date: November 1, 2021
Phase:
Study type: Observational

The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current guidelines available.

NCT ID: NCT03416062 Completed - Jaundice; Malignant Clinical Trials

Remaxol® in Malignant Mechanical Jaundice

Start date: April 3, 2017
Phase: Phase 3
Study type: Interventional

The trial intends to study the safety and efficacy of Remaxol® (succinate + methionine + inosine + nicotinamide; POLYSAN Ltd., Russia),solution for infusion for the reduction of hyperbilirubinemia in patients with obstructive jaundice caused by tumor (malignancy).